Effects of glucagonlike peptide I-(7-36) on release of insulin, glucagon, and somatostatin by rat pancreatic islet cell monolayer cultures
- 1 December 1989
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 38 (12) , 1534-1538
- https://doi.org/10.2337/diabetes.38.12.1534
Abstract
Glucagonlike peptide I (GLP-I-(7–36)) is cleaved from proglucagon in ileal epithelial cells and increases in human plasma after nutrient ingestion. This peptide has been shown to stimulate insulin secretion in vitro and in vivo and thus potentially acts as an incretin. To characterize its action on islet cells, the release of insulin, glucagon, and somatostatin by rat pancreatic islet monolayer cultures at varying concentrations of GLP-I-(7–36) was measured. The interaction of GLP-I-(7–36) with nutrient substrates was assessed by adding amino acids and differing glucose concentrations to the cultures. Islet cell cultures ( n = 5) were incubated for 1 h in medium containing 1.67 or 16.7 mM glucose or 1.67 mM glucose supplemented with amino acids and GLP-I-(7–36) at 10−13−10−7 M. Hormone release was compared with control cultures containing no GLP-I-(7–36); 1.67−16.7 mM glucose with and without GLP-I-(7–36) at 10−11 M; and 1.67, 3.3, 8.3, or 11.1 mM glucose alone or supplemented with amino acids, GLP-I-(7–36) 10−11 M, or both amino acids and GLP-I-(7–36). In medium with 1.67 or 16.7 mM glucose or 1.67 mM glucose and amino acids, GLP-I-(7–36) increased insulin secretion two- to threefold over control at concentrations of 10−9, 10−11, and 10−12 M, respectively. In medium with increasing concentrations of glucose, GLP-I-(7–36) at 10−11 M significantly increased insulin secretion at glucose concentrations ≥3.34 mM. Amino acids and GLP-I-(7–36) combined caused insulin secretion by the monolayer cultures at low glucose concentrations, whereas neither GLP-I-(7–36) nor amino acids alone were stimulatory. At higher glucose concentrations, amino acids and GLP-I-(7–36) together evoked greater insulin release than amino acids or GLP-I-(7–36) alone. With 16.7 mM glucose and GLP-I-(7–36) at 10−9 M, somatostatin release was increased by 40%. Glucagon release was not affected by any concentration of GLP-I-(7–36). Thus, the effect of GLP-I-(7–36) is enhanced in the presence of amino acids and glucose and, at putative physiological levels, is specific for pancreatic β-cells. We conclude that GLP-I-(7–36) is a potent insulinotropin that may be a physiological humoral modulator of nutrient-stimulated insulin secretion.This publication has 13 references indexed in Scilit:
- GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MANPublished by Elsevier ,1987
- Pancreatic and intestinal processing of proglucagon in manDiabetologia, 1987
- Role of pancreatic somatostatin in determining glucagon response to arginine and morphineAmerican Journal of Physiology-Endocrinology and Metabolism, 1987
- Pancreatic somatostatin is a mediator of glucagon inhibition by hyperglycemiaDiabetes, 1987
- Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.Journal of Clinical Investigation, 1987
- Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic isletsDiabetologia, 1985
- Somatostatin in epithelial cells of intestinal mucosa is present primarily as somatostatin 28Peptides, 1984
- Gastric Inhibitory Polypeptide, Cholecystokinin, and Secretin Effects on Insulin and Glucagon Secretion by Islet CulturesExperimental Biology and Medicine, 1979
- Stimulation by Gastric Inhibitory Polypeptide of Insulin and Glucagon Secretion by Rat Islet CulturesExperimental Biology and Medicine, 1978
- The Insulinotropic Effect of Endogenous Gastric Inhibitory Polypeptide in Normal SubjectsJournal of Clinical Endocrinology & Metabolism, 1976